RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--WELIREG Plus LENVIMA Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated RCC Patients. ...

Core Viewpoint - Gold and silver are increasingly viewed as safe-haven assets amid rising economic uncertainty, with significant price increases observed over the past year [1][8]. Precious Metals - Kiyosaki advocates for investing in gold and silver, suggesting that market crashes present opportunities for wealth accumulation [2]. - He predicts that silver prices could reach $200 per ounce by 2026 and sets a target price of $27,000 for gold, citing insights from investment guru Jim Rickards [7]. - Gold prices surged nearly 70% in 2025, reaching an all-time high of over $5,000 per ounce, while silver prices increased over 160% in the same year [8]. Economic Climate - The current market climate is characterized by heightened geopolitical tensions, tariff uncertainties, and potential job displacement due to AI, prompting a reassessment of risk among investors [3]. - Despite the strength of the U.S. stock market, broader economic concerns and layoffs are prevalent, indicating a potential downturn that Kiyosaki has been predicting for over a decade [4]. Cryptocurrency - Kiyosaki also encourages investment in digital assets like bitcoin and Ethereum, asserting that bitcoin's scarcity makes it a valuable asset, with a target price of $250,000 by 2026 [13]. - Bitcoin has experienced significant volatility, with a recent decline of nearly 40% over the past year, highlighting the risks associated with cryptocurrency investments [12][17].

Harbinger, an American medium-duty electric and hybrid vehicle manufacturer, has acquired autonomous driving company Phantom AI. The Garden Grove, Calif.-based company also secured a licensing agreement with ZF Group’s Advanced Driver Assistance Systems (ADAS) business unit for passenger cars. The acquisition, completed in November 2025, was announced Wednesday. It marks Harbinger’s entry into software services and creates a new revenue stream. Under the licensing agreement, ZF will integrate Phantom AI ...

Industry Overview - The cannabis sector is evolving in early 2026, characterized by volatility and pricing pressure for multi-state operators, leading investors to focus on ancillary cannabis stocks instead of direct plant-touching companies [1][3] - Ancillary companies provide essential services such as real estate, financing, or infrastructure support, which can mitigate regulatory risks and offer more stable cash-flow models compared to retail operators [2] Earnings and Market Activity - March 2026 is anticipated to be a pivotal month with earnings updates and ongoing debates about federal reform, while state-level markets remain active and expanding, supporting demand for facilities and capital [3] Investment Metrics - Ancillary cannabis stocks are often evaluated based on fundamentals like AFFO, net interest income, and dividend coverage, making cash flow stability, tenant health, and balance sheet strength critical metrics for investors [4] Key Companies - **Innovative Industrial Properties, Inc. (IIPR)**: A cannabis-focused REIT owning 111 properties across 19 states, generating $66.7 million in revenue and $30.7 million in net income in its latest quarter, with an AFFO per share of $1.88 and a declared dividend of $1.90 per share [6][9] - **NewLake Capital Partners, Inc. (NLCP)**: A smaller cannabis-focused REIT with 34 properties across 12 states, reporting $12.6 million in revenue and $6.7 million in net income, with an adjusted FFO of $11.0 million [10][14] - **Chicago Atlantic Real Estate Finance, Inc. (REFI)**: Operates as a lender to cannabis operators, with a loan portfolio of approximately $400 million, generating net interest income of $13.7 million and a declared dividend of $0.47 per share [15][19] Risk Factors - Tenant credit quality is a significant variable for IIPR, while NLCP's rental income depends on operator performance, making tenant diversification crucial [8][13] - REFI's high yield of 16.5% reflects elevated industry risk but also indicates strong income potential, necessitating close monitoring of borrower performance [20]

Core Viewpoint - The article emphasizes the importance of focusing on stable, high-yield investments in the energy sector, particularly pipeline companies, rather than chasing volatile opportunities linked to fluctuating oil prices. Group 1: Current Oil Market Dynamics - Crude oil prices have been rising due to factors such as a weak dollar, OPEC+ production cuts, and geopolitical tensions, particularly regarding Iran [5] - The current environment has led many investors to pursue high-risk investments, akin to attempting three-point shots in basketball, rather than opting for safer, more reliable options [4][6] Group 2: Investment Opportunities in Energy Infrastructure - Companies that operate pipelines, referred to as "toll takers," benefit from consistent fees regardless of oil prices, making them attractive investments [7] - Enterprise Products Partners LP (EPD) offers a 6.1% distribution yield and has a strong operational track record, including record cash flow and distribution increases [8][9] - Energy Transfer LP (ET) has a 7.1% distribution yield and is actively expanding its infrastructure to support the growing demand from data centers and power plants [10][11] - MPLX LP (MPLX) provides a 7.3% distribution yield and has consistently increased its annual distribution, with several growth projects expected to come online [12][14] - Kimbell Royalty Partners LP (KRP) has an 11.3% dividend yield and operates a unique business model that allows it to benefit from energy price fluctuations while maintaining lower volatility compared to traditional energy stocks [15] - Mach Natural Resources LP (MNR) is a newer player with a 14.8% distribution yield, showing potential for growth despite its current valuation lagging behind the MLP benchmark [17][18]

Core Viewpoint - Netflix's stock surged approximately 13.8% following the company's decision to withdraw from its acquisition bid for Warner Bros. Discovery, which investors interpreted as a disciplined capital allocation move [1][3][4]. Group 1: Acquisition Withdrawal - Netflix announced its exit from the bid for Warner Bros. Discovery's assets, including streaming and studio operations, after declining to match a superior offer from Paramount Skydance valued at around $110 billion [3][4]. - As part of the withdrawal, Netflix received a termination fee of $2.8 billion, which investors viewed positively as it allows the company to refocus on its core streaming business and original content production [4]. Group 2: Analyst Sentiment - Analysts on Wall Street maintain a 'Moderate Buy' rating for Netflix, with 28 out of 37 recent assessments recommending to buy the shares [5]. - The average 12-month price target set by analysts is $114.55, indicating a potential upside of 19.02%, with the highest target at $150 and the lowest at $92 [6]. - Jefferies analysts projected a 10% revenue growth and a 20% compound annual increase in earnings per share, emphasizing strong organic momentum despite concerns over declining hours per subscriber [7]. - Needham's analyst noted that exiting the deal removes regulatory uncertainty and distractions, preserving Netflix's identity as a disruptive force [8]. - Baird's analyst expects the withdrawal to trigger a recovery in Netflix shares by alleviating uncertainty surrounding the stock [9]. - KeyBanc Capital Markets highlighted the importance of continued investment in original programming and live events to sustain engagement and monetization [10].

Core Insights - Emergent BioSolutions Inc. (EBS) experienced a significant decline of approximately 27% in its stock price on Friday, primarily attributed to factors beyond its 2025 results [1]. Company Overview - Emergent BioSolutions is involved in the biotechnology sector, focusing on drug development and therapeutic research [1]. - The company aims to innovate through unique mechanisms of action and first-in-class therapies, which could potentially reshape treatment paradigms [1]. Analyst Perspective - The analysis emphasizes the importance of combining scientific expertise with financial and market analysis to deliver technically sound and investment-driven research [1]. - The focus is on evaluating the science behind drug candidates, the competitive landscape, clinical trial design, and potential market opportunities while balancing financial fundamentals and valuation [1].

Software stocks as a whole have been getting slammed in recent weeks. There's really only one culprit for this mess: Anthropic. Anthropic is a leading company in the generative AI space, and is seen as the leader in coding generative AI. Some of its products have made it possible to write programs that replace several software products for which companies pay millions. This has caused several software stocks to tumble in valuation, as the market is unsure about their future.Recently, Anthropic released its ...

Core Insights - Cogent Biosciences announced additional clinical results from the SUMMIT trial for bezuclastinib in patients with NonAdvanced Systemic Mastocytosis (NonAdvSM), showing significant improvements across primary and secondary endpoints [1][2] Group 1: Clinical Results - Bezuclastinib demonstrated a mean change of -32.0 points in Total Symptom Score (TSS) at 48 weeks, indicating a 56% relative improvement from baseline [5][6] - 99% of patients achieved over 50% reduction in serum tryptase levels, with 83% normalizing their levels [6][11] - Significant improvements were observed across various symptoms, including a 65% reduction in dermatologic symptoms and a 53.6% reduction in neurocognitive symptoms [4][11] Group 2: Safety and Tolerability - Bezuclastinib exhibited a favorable safety and tolerability profile, supporting its potential for chronic use in NonAdvSM patients [7][11] Group 3: Market Position and Future Potential - The company believes bezuclastinib has the potential to become the preferred standard of care for NonAdvSM patients due to its rapid and meaningful symptom improvement [2][10] - The treatment is positioned as the first disease-modifying agent for NonAdvSM, with strong evidence correlating serum tryptase reduction with symptomatic improvement [5][11] Group 4: Inducement Grants - Cogent announced inducement equity awards to three new employees, including nonqualified options to purchase 24,000 shares and 21,000 restricted stock units (RSUs) [8]

Berkshire Hathaway's Earnings Are Nearly Here. Greg Abel's Letter Will Be Top of Mind for Investors. - Barron'sSkip to Main ContentThis copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.# Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buyba ...